These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34348575)

  • 1. Review of Preclinical Outcomes of a Topical Cationic Emulsion of Cyclosporine A for the Treatment of Ocular Surface Diseases.
    Daull P; Baudouin C; Liang H; Feraille L; Barabino S; Garrigue JS
    Ocul Immunol Inflamm; 2022; 30(7-8):1945-1955. PubMed ID: 34348575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
    Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
    Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.
    Leonardi A; Van Setten G; Amrane M; Ismail D; Garrigue JS; Figueiredo FC; Baudouin C
    Eur J Ophthalmol; 2016 Jun; 26(4):287-96. PubMed ID: 27055414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies.
    Leonardi A; Messmer EM; Labetoulle M; Amrane M; Garrigue JS; Ismail D; Sainz-de-la-Maza M; Figueiredo FC; Baudouin C
    Br J Ophthalmol; 2019 Jan; 103(1):125-131. PubMed ID: 29545413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye.
    Baudouin C; Figueiredo FC; Messmer EM; Ismail D; Amrane M; Garrigue JS; Bonini S; Leonardi A
    Eur J Ophthalmol; 2017 Aug; 27(5):520-530. PubMed ID: 28362054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye.
    Daull P; Feraille L; Barabino S; Cimbolini N; Antonelli S; Mauro V; Garrigue JS
    Exp Eye Res; 2016 Dec; 153():159-164. PubMed ID: 27777121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the efficacy of 0.1% cyclosporine A cationic emulsion in the treatment of dry eye disease during COVID-19 pandemic.
    Stopyra W
    Rom J Ophthalmol; 2023; 67(2):164-168. PubMed ID: 37522012
    [No Abstract]   [Full Text] [Related]  

  • 8. Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials.
    Shen Lee B; Toyos M; Karpecki P; Schiffbauer J; Sheppard J
    Ophthalmol Ther; 2022 Aug; 11(4):1333-1369. PubMed ID: 35608780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Switching from Cyclosporine A 0.05% Anionic Emulsion to Cyclosporine A 0.1% Cationic Emulsion in Patients with Dry Eye Associated with Sjögren's Syndrome.
    Kim J; Moon TK; Yoon HJ; Ji YS; Yoon KC
    J Ocul Pharmacol Ther; 2021 Oct; 37(8):472-478. PubMed ID: 34449255
    [No Abstract]   [Full Text] [Related]  

  • 10. Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study.
    Labetoulle M; Leonardi A; Amrane M; Ismail D; Garrigue JS; Garhöfer G; de la Maza MS; Baudouin C
    Clin Ther; 2018 Nov; 40(11):1894-1906. PubMed ID: 30389343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world insights and outcomes related to ciclosporin A 0.1% cationic emulsion for the long-term treatment of dry eye disease in Germany: Country-level sub-analysis of the PERSPECTIVE study.
    Lanzl I; Deuter CME; Lorenz K; Geerling G;
    Graefes Arch Clin Exp Ophthalmol; 2024 Oct; 262(10):3261-3271. PubMed ID: 38722320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease.
    Labetoulle M; Garhöfer G; Ismail D; Garrigue JS; Amrane M; Guillon M; Aragona P; Baudouin C
    Acta Ophthalmol; 2024 Jun; 102(4):382-390. PubMed ID: 38294079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cationic Emulsion-Based Artificial Tears as a Mimic of Functional Healthy Tear Film for Restoration of Ocular Surface Homeostasis in Dry Eye Disease.
    Daull P; Amrane M; Ismail D; Georgiev G; Cwiklik L; Baudouin C; Leonardi A; Garhofer G; Garrigue JS
    J Ocul Pharmacol Ther; 2020; 36(6):355-365. PubMed ID: 32493105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen.
    Chan YH; Sun CC
    Taiwan J Ophthalmol; 2023; 13(1):68-74. PubMed ID: 37252163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of 0.1% cyclosporin A cationic emulsion and 0.05% cyclosporin A emulsion in murine dry eye cases with different severities.
    Jin R; Li Y; Li L; Kim J; Yoon HJ; Yoon KC
    Exp Ther Med; 2021 Dec; 22(6):1363. PubMed ID: 34659509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.
    Rodriguez-Aller M; Kaufmann B; Guillarme D; Stella C; Furrer P; Rudaz S; El Zaoui I; Valamanesh F; Di Tommaso C; Behar-Cohen F; Veuthey JL; Gurny R
    Eur J Pharm Biopharm; 2012 Apr; 80(3):544-52. PubMed ID: 22155591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The place of ciclosporin A cationic emulsion 0.1% in the therapy of xerophthalmia].
    Maychuk DY; Yani EV; Brzheskiy VV; Grishina EE; Drozdova EA; Maychuk NV; Panova IE; Safonova TN
    Vestn Oftalmol; 2024; 140(2):102-111. PubMed ID: 38742506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials.
    Leonardi A; Doan S; Aragona P; Amrane M; Ismail D; Montero J; Németh J; Bremond-Gignac D
    Eye (Lond); 2023 Aug; 37(11):2320-2326. PubMed ID: 36564576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis.
    Karpecki P; Barghout V; Schenkel B; Huynh L; Khanal A; Mitchell B; Yenikomshian M; Zanardo E; Matossian C
    BMC Ophthalmol; 2023 Nov; 23(1):443. PubMed ID: 37919692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of topical cyclosporine 0.05% and osmoprotective lubricating eye drops in treating dry eye disease and inflammation.
    Mullick R; Annavajjhala S; Thakur P; Mohapatra A; Shetty R; D'Souza S
    Indian J Ophthalmol; 2021 Dec; 69(12):3473-3477. PubMed ID: 34826977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.